Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab
Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab
复制标题
DOI：
10.1016/j.ajo.2004.06.077
复制
发表时间：
2004-12-01
影响因子：
4.2
通讯作者：
Waitzman, DM
中科院分区：
文献类型：
--
作者：
Garrity, JA;Coleman, AW;Waitzman, DM
目的：报告针对肿瘤坏死因子 α 的单克隆抗体（英夫利昔单抗）对 7 名慢性且难以控制的特发性眼眶炎症（眼眶肌炎）患者的治疗结果。设计：观察性病例系列。方法：收集了 7 名在三个医疗中心接受评估的特发性眼眶炎症患者的回顾性数据。所有患者在传统治疗（包括皮质类固醇、放疗或抗炎化疗药物）失败后均接受英夫利昔单抗治疗。 结果：所有 7 名患者对英夫利昔单抗治疗均有良好反应。一名白塞病患者需要补充口服皮质类固醇。疼痛、肿胀和是否需要同时使用皮质类固醇是治疗成功的主要衡量标准。四名患者的共病症状也得到改善（两名患者为克罗恩病，一名患者为白塞病，一名患者为牛皮癣）。平均随访 15.7 个月（范围为 4 至 31 个月）后，治疗没有出现不良反应。结论：对于传统治疗失败的顽固性或复发性特发性眼眶炎症，英夫利昔单抗治疗似乎提供了另一种治疗选择。 (C) 2004 年，Elsevier Inc. 保留所有权利。
PURPOSE: To report results of treatment with a mono, clonal antibody (infliximab) directed against tumor necrosis factor alpha in seven patients with chronic and difficult-to-control idiopathic orbital inflammation (orbital myositis).DESIGN: Observational case series.METHODS: Retrospective data were collected from seven patients who had idiopathic orbital inflammation and who were evaluated at three medical centers. All patients were treated with infliximab after the failure of traditional therapy, which included corticosteroids, radiotherapy, or anti, inflammatory chemotherapeutic agents.RESULTS: All seven patients had a favorable response to treatment with infliximab. One patient with Behcet disease required supplemental oral corticosteroids. Pain, swelling, and need for concomitant corticosteroids were the primary measures of treatment success. Symptoms of comorbid disease in four patients also improved (Crohn disease in two, Behcet disease in one, and psoriasis in one). There were no untoward effects of treatment after a mean follow-up of 15.7 months (range, 4 to 31 months).CONCLUSIONS: Treatment with infliximab appears to offer another therapeutic option in cases of recalcitrant or recurrent idiopathic orbital inflammation in which conventional treatment fails. (C) 2004 by Elsevier Inc. All rights reserved.